Clinical Trials for Kidney Cancer

A Phase 2, Open-label, Multicenter Study of IBI363 (PD1-IL2m) in Subjects with Advanced Solid Malignancies

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial involves adult patients with advanced solid tumors who have limited treatment options, evaluating the efficacy and safety of IBI363, a PD-1/IL-2α-bias bispecific antibody fusion protein targeting the PD-1/PD-L1 pathway and activating the IL-2 pathway to enhance tumor-specific T cell activity.

ClinicalTrials.gov ID: NCT06281678

Phase 2 Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Previously untreated adults with unresectable/metastatic clear cell RCC (all IMDC risk groups; ECOG 0–2; treated/stable brain mets allowed) are randomized to botensilimab (Fc‑enhanced anti‑CTLA‑4) plus balstilimab (anti‑PD‑1) versus standard ipilimumab/nivolumab. The trial compares objective response and durability/safety, with early efficacy focus on intermediate/poor risk disease.

ClinicalTrials.gov ID: NCT05928806

Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Adults with metastatic/advanced clear cell RCC who progressed after at least one systemic line including a PD-1/PD-L1 inhibitor (two cohorts based on prior VEGF/HIF-2α exposure) receive ivonescimab monotherapy IV q3w. Ivonescimab is a bispecific PD-1/VEGF antibody designed to simultaneously restore antitumor immunity and inhibit angiogenesis.

ClinicalTrials.gov ID: NCT06940518

EXACT: Randomized Phase II Trial of XL092 in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Adults with advanced/metastatic clear cell RCC who progressed on or after adjuvant anti–PD-1/PD-L1 therapy (no prior systemic therapy otherwise) are randomized to zanzalintinib (XL092), an oral multi-targeted TKI of VEGFR2/MET/TAM kinases, versus XL092 plus nivolumab (PD-1 inhibitor). Key exclusions include untreated/unstable CNS mets and active autoimmune disease requiring immunosuppression.

ClinicalTrials.gov ID: NCT06863311

A Phase Ib/III Randomized, Multicenter, Global Study of Volrustomig Plus Casdatifan or Volrustomig Monotherapy Versus Nivolumab Plus Ipilimumab as First-line Treatment for Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Untreated adults with advanced/metastatic clear cell RCC (KPS ≥70%) are randomized to volrustomig (a PD‑1/CTLA‑4 bispecific designed to preferentially inhibit CTLA‑4 on PD‑1+ T cells) plus casdatifan (oral HIF‑2α inhibitor), volrustomig alone, or standard nivolumab/ipilimumab. Key exclusions include symptomatic CNS disease and active autoimmune disorders; endpoints focus on PFS/OS versus nivo/ipi.

ClinicalTrials.gov ID: NCT07000149

Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: The trial investigates APL-101, a selective c-MET receptor tyrosine kinase inhibitor, in adult patients with NSCLC exhibiting c-Met exon 14 skipping mutations, various solid tumors with MET alterations, and primary CNS tumors. It includes APL-101 monotherapy and combination therapy with EGFR inhibitors in cases of acquired MET amplification resistance.

ClinicalTrials.gov ID: NCT03175224

Phase II Trial of Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Selected Solid Tumor Malignancies

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Adults with advanced solid tumors after ≥1 prior therapy, enriched for ARID1A-altered cancers, ATM-deficient tumors (including mCRPC), and a post–checkpoint inhibitor endometrial cancer cohort; measurable disease required. Patients receive the ATR inhibitor ceralasertib (monotherapy for BAF250a-negative ARID1A or ATM-loss, ceralasertib + PARP inhibitor olaparib for BAF250a-positive ARID1A, or ceralasertib + anti–PD-L1 durvalumab for endometrial), leveraging DNA damage response targeting and potential synergy with PARP inhibition or immunotherapy.

ClinicalTrials.gov ID: NCT03682289

Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure of Rituximab or Rituximab and Chemotherapy

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Adults and children with biopsy-proven EBV-positive PTLD after solid organ or allogeneic HCT who have failed rituximab (± chemotherapy for SOT) receive tabelecleucel, an allogeneic, off‑the‑shelf EBV‑specific cytotoxic T‑cell therapy matched by HLA and infused on days 1, 8, and 15 of 35‑day cycles. Excludes T‑cell lymphomas, active/untreated CNS PTLD, significant GVHD, recent checkpoint inhibitors or EBV‑directed cell therapies, and requires measurable FDG‑avid disease and adequate organ function.

ClinicalTrials.gov ID: NCT03394365

STING Agonist and Personalized Ultra-fractionated Stereotactic Adaptive Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer (SPARK)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with metastatic clear-cell RCC showing oligoprogression (1–3 lesions) after prior anti–PD-1/CTLA-4 therapy receive continued nivolumab plus PULSAR stereotactic adaptive radiotherapy to all progressing sites, with one lesion also injected intratumorally with the STING agonist IMSA101 (2′3′-cGAMP analog activating TMEM173 to induce type I IFNs) over five doses. Requires at least one safely injectable non-lung lesion; excludes progressive ultracentral/central chest lesions.

ClinicalTrials.gov ID: NCT06601296

A Randomized, Phase 3, Double-blind, Placebo-controlled Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma(RENAVIV)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Adults with unresectable locally advanced or metastatic clear cell RCC, VEGF TKI–naive (allowing ≤1 prior line of cytokine or ICI), are randomized to pazopanib plus the pan–HDAC inhibitor abexinostat versus pazopanib alone. Abexinostat (HDAC class I/II inhibitor that may enhance VEGF-TKI sensitivity via HIF-1α downregulation) is given intermittently with continuous daily pazopanib; crossover to the combination is allowed at progression from the control arm.

ClinicalTrials.gov ID: NCT03592472